94 results about "Antidepressant medication" patented technology

The invention discloses an antidepressant drug compliance management system based on biological feature recognition and a method thereof, and belongs to the field of medical health systems. The system comprises a biological characteristic acquisition module for acquiring multi-modal biological characteristic data of a drug user in real time; the identity authentication module is used for verifying the identity of a medicine user to prevent illegal use or cheating behaviors; the medicine taking behavior management module is responsible for analyzing the behavior sequence of the medicine taking person in real time, identifying the appearance characteristics of the medicine and verifying the accuracy of the medicine taking action; the data analysis module performs cleaning, feature extraction and pattern analysis on the collected data, constructs a personalized medication behavior model and predicts a medication trend; the abnormity monitoring and early warning module is used for carrying out real-time monitoring and risk assessment on medication behaviors through a comprehensive risk assessment mechanism and generating early warning information and intervention suggestions of corresponding levels; and the interaction management module provides a self-adaptive user interface and is responsible for information display, medication reminding pushing and data visual presentation.

The invention belongs to the technical field of biomedicine, and particularly relates to a benzenesulfonamide derivative and application of the benzenesulfonamide derivative in antidepressant drugs. The structural general formula of the compounds is (I), the compounds or pharmaceutically acceptable salts thereof have agonistic activity on 5-hydroxytryptamine 2A type receptors, and the compounds are determined to have good anti-depression activity through a mouse tail suspension experimental model, an open field experimental model and a forced swimming experimental model. The compound is an anti-depression compound which is novel in structure and wide in application prospect, has no magical effect, and can be developed into an anti-depression treatment medicine.

The invention belongs to the technical field of biomedicine, and particularly relates to application of carboline compounds in preparation of antidepressant drugs. According to the present invention, the carboline compound or the pharmaceutically acceptable salt thereof can target the 5-HT2A receptor, and has the 5-HT2A receptor excitation activity; the compound can effectively relieve depression symptoms of mice in a mouse spontaneous activity experiment model, a tail suspension experiment model and an open field experiment model under the dosage of 10 mg / kg-20 mg / kg. As an anti-depression drug, compared with an existing 5-HT2A agonist, the compound has a relatively strong anti-depression effect, but the carboline compound does not have a magical effect and has a prospect of being developed into an anti-depression treatment drug.

The invention belongs to the field of antidepressant drugs, and discloses an antidepressant composition containing compound liquorice tablets and application of the antidepressant composition. The composition obtained by compounding the compound licorice tablets and various traditional Chinese medicine extracts has the effects of soothing liver-qi stagnation, calming heart and tranquilizing mind, nourishing blood and regulating liver, and treating qi and blood at the same time, can significantly improve depressive symptoms caused by LPS stimulation, and has a good anti-depression effect. On the basis, a fingerprint control mode based on the dual-wavelength high performance liquid chromatography standard characteristics of the compound liquorice tablets is established. According to the method, macro qualitative similarity and macro quantitative similarity are used for checking the change range of the overall component content and the quality consistency control condition of the compound liquorice tablets. The quality consistency of the compound liquorice tablets is finally not less than 0.95 in terms of macro qualitative similarity of 220nm and 260nm high performance liquid chromatography fingerprints, the macro quantitative similarity is between 85% and 115%, and the compound liquorice tablets have the effect of improving the depression behavior of mice caused by LPS (Lipopolysaccharide).

The invention relates to the technical field of psychiatric pharmacology, discloses application of helicid in antidepressant drugs, and aims to solve the problems of large side effect, unstable curative effect, drug resistance and the like of existing antidepressant drugs. According to the medicine, through multiple mechanisms of activating a cAMP / PKA / CREB signal channel, promoting neuroplasticity, inhibiting neuronal apoptosis, relieving neuroinflammation and the like, the depressive symptom is remarkably improved. The preparation method comprises the steps of extraction and purification of helicid and preparation of the medicinal preparation. Animal experiments verify that the hilicidum-based antidepressant drug can effectively improve behavioral indexes of depression model rats, has low side effects, and does not have the problem of drug resistance. Compared with the traditional medicine, the medicine provided by the invention has the advantages that the treatment effect is improved, the adverse reaction is reduced, the application prospect is better, and a new medicine choice with a multi-target action mechanism is provided for the treatment of depression.

The invention relates to the field of biological medicine, in particular to vortioxetine and application of pharmaceutically acceptable salts, solvates, crystal forms and prodrugs of vortioxetine to preparation of drugs for preventing or treating pathogenic fungal infection. The application reveals that the antidepressant vortioxetine (vortioxetine) and hydrobromide thereof (vortioxetine. HBr) which are sold on the market have measurable in-vitro inhibitory activity on various clinical common pathogenic fungi for the first time, so that the pharmacological action spectrum of the compound is expanded, and a new candidate direction is provided for research and development of antifungal drugs; the application not only overcomes the defects of existing antifungal drugs in the aspects of drug resistance, biological membranes and safety, but also opens up a brand new application direction of mental small molecule drugs in the anti-infection field, and has remarkable technical innovation, social value and industrial popularization prospect. The application also provides a theoretical basis for establishing a'multi-modal micromolecular antifungal library ', and can promote the development of pharmacological mechanism research and fungal infection precise treatment.

The present invention relates to a combination, a combination for treating a psychiatric disorder in a patient, a method for treating a psychiatric disorder in a patient, a kit, a dosing regimen, a delivery device, a method of adjuvant therapy, a short-acting magical agent for treating a psychiatric disorder in a patient or a parenteral formulation for treating a psychiatric disorder in a patient. In particular, the present invention relates to the combined administration of a short acting magical agent with a monoamine antidepressant, such as a selective serotonin reuptake inhibitor (SSRI).

The invention discloses an application of indole-3-formaldehyde in preparation of antidepressant drugs, and relates to the technical field of medicines.The antidepressant drugs comprise active ingredients and pharmaceutical excipients, the active ingredients comprise indole-3-formaldehyde or pharmaceutically acceptable salts thereof, and the effective dose of the active ingredients in rats is 70-200 mg / kg; indole-3-formaldehyde is adopted, so that depression-like behaviors of mice can be remarkably improved, the indole-3-formaldehyde can be used as an exogenous oral supplement to enter intestinal tracts and even can penetrate through a blood brain barrier to enter brain tissues, and the anti-depression effect is achieved from the two aspects of improving the intestinal steady state and protecting neuroinflammation. The tryptophan intestinal metabolite is applied to treatment and improvement of depression for the first time, and a theoretical basis and a novel angle are provided for subsequent research and development of antidepressant drugs applying the tryptophan intestinal metabolite.

The invention discloses a compound with remarkable 5-hydroxytryptamine (5-HT) reuptake inhibition activity, a preparation method of the compound and application of the compound in preparation of anti-depression drugs. And the compound is a compound Oreonudine C. The invention further discloses a preparation method of the compound. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, and performing silica gel column chromatography, C18 ODS column chromatography and preparative high performance liquid chromatography on the chloroform extraction part to obtain the Oreonudine C. The invention further discloses a preparation method of the Oreonudine C. The preparation method of the Oreonudine C comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, and obtaining the Oreonudine C. In-vitro experiments show that the compound Oreonudine C remarkably inhibits reabsorption of 5-HT (the inhibition rate is 60.4%) in mouse hippocampal neuronal cells HT22, and the inhibition rate of the compound Oreonudine C is superior to that of a positive control drug amitriptyline (the inhibition rate is 53.6%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The present invention relates to an antidepressant, anti-anxiety, anti-stress, tension-relieving or stress-relieving composition containing a fermented Perilla frutescens extract. In addition, the present invention relates to a fermented Perilla frutescens extract-containing composition for preventing, ameliorating, or treating stress-related disorders, depression, or anxiety. In addition, the present invention relates to a fermented Perilla frutescens extract-containing fiber or fragrance composition for relieving depression, anxiety, tension, or stress. In addition, the present invention relates to a method for treating depression or anxiety, the method comprising administering a fermented Perilla frutescens extract to a patient suffering from a stress-related disorder, depression, or anxiety. A fermented Perilla frutescens (Perilla frutescens Britton var. acuta Kudo (Chajgi), or Perilla frutescens Britton var. crispa Decaisn (Jasoyeop)) extract according to the present invention significantly relieves stress compared to an unfermented Perilla frutescens extract, and thus can be used as an antidepressant, anti-anxiety, tension-relieving or stress-relieving composition, and furthermore, can be effectively used in a composition or therapeutic method for preventing, ameliorating, or treating stress-related disorders, depression, and anxiety.

The application belongs to the technical field of biomedicine, and particularly relates to a benzene sulfonamide derivative and application thereof in antidepressant drugs. The structural general formula of the compound is (I). The compound or a pharmaceutically acceptable salt thereof has agonistic activity on 5-hydroxytryptamine 2A type receptors. The compound is determined to have good antidepressant activity through a mouse tail suspension test model, an open field test model and a forced swimming test model, is a novel antidepressant compound with wide application prospect, has no hallucinogenic effect, and can be developed into an antidepressant therapeutic drug.

The invention provides an application of lilium lancifolium exosome in preparation of a medicine for treating depression. The lilium lancifolium exosome has a unique nano-structure, is better in biocompatibility, can accurately target pathological cells, penetrate a biological membrane and a blood brain barrier, reduces damage to normal cells, directly acts on a central nervous system, is less in dosage, is safer in clinical use, has many side effects when being used as an antidepressant drug, and is high in treatment resistance and recurrence risk, and the like. A brand-new efficient solution is provided, and existing treatment bottlenecks are expected to be broken through.

The invention discloses application of dimethyl fumarate in preparation of a medicine for treating depression, and relates to the technical field of medicine research and development. Comprising experimental verification and medicine preparation, and the medicine preparation comprises the following steps: raw material preparation: weighing a dimethyl fumarate raw material and a medicinal carrier in proportion; uniformly mixing: fully mixing the dimethyl fumarate and the medicinal carrier by using a three-dimensional mixer or a double-cone mixer; granulating: adding a wetting agent for fluidized bed granulation or wet granulation to form granules with set sizes; granulating and drying: granulating the wet granules, drying, and controlling the water content of the granules; forming is conducted; and packaging: packaging the prepared medicine, and labeling information. The dimethyl fumarate is applied to the field of depression treatment, experiments verify that the dimethyl fumarate has a remarkable improvement effect on depression-like behaviors induced by chronic social contusion stress, and a new direction is provided for development of anti-depression drugs.

The invention discloses a fluvoxamine maleate tablet and a preparation method thereof, the fluvoxamine maleate tablet is prepared from the following raw materials in parts by mass: 45 to 55 parts of fluvoxamine maleate, 145 to 155 parts of mannitol, 38 to 42 parts of corn starch, 3 to 8 parts of pregelatinized starch, 0.5 to 1 part of colloidal silicon dioxide and 1.5 to 2 parts of sodium stearyl fumarate, and corn starch accounting for 4.4-5.6% of the total mass is used as a starch slurry raw material. By adopting a wet granulation process, the granules are good in flowability and compressibility, qualified in quality, stable in property, high in release speed and high in solubility, and the dissolution rate of the granules in different pH environments and water media for 15 minutes is greater than 85%. Compared with the traditional antidepressant drug, the fluvoxamine maleate and the pseudoadrenaline have low efficacy and are not easy to cause excitement, hidrosis and other symptoms; the anti-choline and anti-histamine efficacy is low, and the phenomena of weight gain, drowsiness and the like are rarely caused; the interaction among the medicines is small, and the drug combination is facilitated.

The invention relates to application of broad bean pyrimidine in preparation of antidepressant drugs, and belongs to the technical field of biological medicines. Depression is a common and high-disability heavy mental disorder, has the core characteristics of remarkable and lasting emotion lowering and interest loss, seriously damages the social functions and life quality of patients, and has become one of the major public health burdens in the world. Based on new cognition of complex mechanisms of diseases, a new generation of antidepressant drugs which have a brand new action mechanism, can more accurately intervene in core pathological links of the diseases and can better meet the clinical requirements are researched and developed, and the new generation of antidepressant drugs are not only an inevitable direction for promoting psychopharmacology progress, but also are urgent medical necessities for improving prognosis of hundreds of millions of patients and relieving social burdens. A per2- / -mutant zebrafish depression model is used for performing drug screening on traditional Chinese medicine monomers, and finally it is found that 10 mM of broad bean pyrimidine has the anti-depression characteristic and can effectively improve the depression-like phenotype of per2- / -mutant zebrafish.

The present invention relates to combinations, combinations for use, methods of treatment, kits, dosing regimens, delivery devices, adjunctive treatment methods, short-acting psychedelic agents for use, or parenteral formulations for use, for treating mental disorders in patients. In particular, the present invention relates to administering short-acting psychedelic agents in combination with monoamine antidepressants, such as selective serotonin reuptake inhibitors (SSRIs).

The invention belongs to the field of medicines, and relates to application of 3, 5-dimethoxy-4 '-hydroxystilbene in preparation of antidepressant medicines, in particular to a 3, 5-dimethoxy-4'-hydroxystilbene oral preparation and application of the 3, 5-dimethoxy-4 '-hydroxystilbene oral preparation in preparation of rapid and efficient antidepressant medicines, and the component is taken orally and has rapid and remarkable efficacy.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a preparation method of compound radix bupleuri depression-relieving dropping pills and application of the compound radix bupleuri depression-relieving dropping pills in antidepressant drugs. According to the dropping pill preparation, medicine simplification and optimization are carried out on the basis of Xiaoyao powder, meanwhile, the dissolution rate of insoluble components is improved by adopting a solid dispersion technology, the formability and the medicine loading capacity of the dropping pill are optimized by using a compound matrix and a nano flow aid, and the slow-release coating technology meets the slow-release requirement of circadian rhythmic depression. Meanwhile, the dissolution rate and the stability of effective components are improved, and the sustained release characteristic is achieved, so that the composition is suitable for preventing and treating depression.

The invention belongs to the technical field of medicines, and particularly relates to an esketamine and mirtazapine synergistic antidepressant pharmaceutical composition and application thereof. The antidepressant pharmaceutical composition comprises the following active components: esketamine and mirtazapine, the esketamine is an N-methyl-D-aspartic acid receptor antagonist, and the mirtazapine is an adrenergic alpha2-AR antagonist. According to the anti-depression pharmaceutical composition containing esketamine and mirtazapine, through the synergistic effect of esketamine and mirtazapine, the effects of reducing dosage, prolonging aging and reducing adverse reactions are achieved, and major depressive disorder is safely and effectively prevented and treated.

The present invention provides an antidepressant preparation for nasal mucosa administration, its preparation method and application, which relates to the field of medicine. The antidepressant preparation is prepared from the following raw materials: hydroxytyrosol-Angiopep-2 complex, poloxamer, sodium hyaluronate and water; the hydroxytyrosol-Angiopep-2 complex is prepared from hydroxytyrosol and Angiopep-2 with a molar ratio of 1:0.05 to 0.2; the weight-average molecular weight of sodium hyaluronate is 60 to 120 kDa. The antidepressant preparation of the present invention can not only increase the stability of hydroxytyrosol, but also facilitate the delivery of hydroxytyrosol to the brain tissue at a steady rate, directly enter the brain to exert antidepressant efficacy, reduce the number of drug administrations, and better exert the antidepressant activity of hydroxytyrosol. The antidepressant preparation of the present invention has the advantages of long-lasting efficacy and convenient use, and also has the characteristics of good dispersibility, strong adhesion, good stability, and the ability to maintain a local high concentration at the administration site.

The present application relates to novel compounds that are prodrugs of brexpiprazole. The novel compounds of the present invention, upon administration to a subject, undergo chemical conversion by one or more metabolic processes to release the active agent in vivo. Brexpiprazole sold by Rexulti (registered trademark) is an atypical antipsychotic drug, is suitable for being used as an adjuvant therapy of an antidepressant drug, and is used for treating major depressive disorder (MDD) of adults and schizophrenia of adults and children patients over 13 years old. # imgabs0 #

The invention discloses a method for synthesizing amide through oxidative cross-coupling of aldehyde amine driven by visible light and application, and the method comprises the following steps: S100, sequentially adding 20mg of high-crystallinity B / P co-doped g-C3N4 nanosheet, 20mg of potassium carbonate, 20mL of acetonitrile, 1mmol of aldehyde compound and 1mmol of amine compound into a quartz photoreaction flask equipped with magnetic stirring and circulating cooling water, and reacting at room temperature and normal pressure for 2-4 hours; performing dark reaction for 0.5 hour; wherein the B / P co-doped g-C3N4 nanosheet with high crystallinity is used as a heterogeneous photocatalyst; the method comprises the following steps: S101, turning on a 60W blue LED lamp for irradiation, and reacting for 12 hours under the conditions of continuous bubbling and air introduction; wherein the air introduction speed is 1-2 ml / min; and S102, centrifugally separating out the catalyst, drying an organic phase by using anhydrous magnesium sulfate, and carrying out suction filtration and rotary evaporation to obtain a target product, the visible light driven aldehyde amine oxidation cross coupling synthesized amide compound moclobemide prepared by the method can be used as an antidepressant drug and is applied to the field of medicine.

This invention provides a method for predicting antidepressant drugs. Based on a combination of knowledge graph, transcriptomics, and machine learning technologies, it screens potential drugs for depression. Specifically, it integrates disease-related node files, relation files, and transcriptomic data to construct information in triplet form, which is then imported into a model and converted into digital tensor information for scoring. The training dataset includes antidepressant tags from ClinicTrials and DrugBank, as well as other non-antidepressant drugs, combined with differential gene expression data obtained using RNA-seq technology. Multiple scoring models, such as TransE, TransR, DistMult, and ComplEx, are used for training and evaluation to screen potential antidepressant drugs. This method has the advantages of low cost, high efficiency, and wide applicability, significantly improving the accuracy and efficiency of antidepressant drug screening, providing a new drug discovery pathway for the treatment of depression, and helping to accelerate the research and development process of antidepressant drugs.

Milanserin hydrochloride is an effective antidepressant drug, and development of an efficient and green synthetic method for preparing the drug intermediate is of great significance. According to the invention, 2-benzylaniline is adopted as a raw material, and an intermediate compound 7 is obtained with high yield through four steps of reaction of amidation, cyclization, ammonification and reductive amination cyclization. The compound 7 is further converted to obtain a mianserin API molecule, and a high-purity target product can be prepared by further recrystallization. The method has the advantages of high product yield and stable quality; the method has the characteristics of simple operation process and small environmental pollution, and meets the requirements of industrial clean production.

The invention belongs to the field of biological medicine, and particularly relates to a method and a system for curative effect evaluation and drug withdrawal decision support of depression drugs. It has been found that the platelet 5-HT concentration can be used as an objective index of the curative effect of the antidepressant drug and drug withdrawal indication, a drug withdrawal decision-making system based on the platelet 5-HT concentration is constructed, and the platelet 5-HT concentration is combined with the blood concentration of the drug, the HAMD score of a depression patient and basic information of the depression patient. Compared with a conventional decision making system, the specific decision making formula designed by the invention can be used for realizing a more accurate drug withdrawal decision. In addition, a drug withdrawal decision-making system and a drug effect evaluation method based on the platelet 5-HT concentration are combined, and a complete depression drug effect evaluation and drug withdrawal decision-making system suitable for clinical application is developed.

The invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt, a prodrug, a deuterated compound, a hydrate, a solvate, an enantiomer, a diastereoisomer or a racemate thereof, and a preparation method and application thereof. Application of compounds in preparation of anti-depression drug # imgabs0 # capable of taking effect quickly

The invention belongs to the technical field of crystal form medicine preparation, and particularly relates to a preparation method of a high-stability vortioxetine hydrobromide crystal form alpha. The vortioxetine hydrobromide is an antidepressant drug which is widely applied at present, and the crystal form alpha of the vortioxetine hydrobromide is relatively high in solubility and relatively good in bioavailability, but the vortioxetine hydrobromide is unstable and is easily transformed into a crystal form beta. The preparation method comprises the following steps: adding vortioxetine hydrobromide into an alcohol-water mixed solution for fully dissolving, applying a direct-current electric field to induce the formation of the crystal form alpha, and controlling the cooling rate to grow the crystal for 1-2 hours, so that the crystal form alpha with high purity and good stability is prepared, does not generate crystal transformation after being placed for a long time, and has better safety when being applied to a clinical preparation.

The invention relates to an anti-depression compound 4-methyl-6-methoxy coumarin, and belongs to the technical field of biological medicines. Depression is the most common mental disorder in the world and is also a main reason for disability. The development of a novel anti-depression drug which is based on a nerve plasticity mechanism, takes effect quickly, has a lasting curative effect and is high in safety, and particularly has important clinical requirements and technical necessity for an effective treatment means for refractory depression. Traditional Chinese medicine monomers and a per2- / -zebra fish depression model are adopted for anti-depression drug screening, and finally it is found that 10 mM of 4-methyl-6-methoxycoumarin has the anti-depression characteristic and has the positive treatment effect on the exploration behavior, social interaction and sleep-awakening period of per2- / -zebra fish. The method can effectively rescue and reverse depression-like phenotypes observed in a per2- / -zebra fish circadian rhythmic depression model, and can restore the balance of important gene expression.

The application belongs to the technical field of medicine, and discloses a combined medicine for treating depression and application thereof. The combined medicine provided by the application comprises an antidepressant and artemisia indica simultaneously administered and / or sequentially administered. The application realizes the antidepressant effect of the combined use of the antidepressant and artemisia indica, effectively prevents and reduces liver injury caused by the antidepressant, expands the user group of the antidepressant, and has important significance in the clinical treatment of depression.

The invention discloses application of calmodulin gamma CaMKII in hippocampal astrocyte as a target spot in screening or preparing a medicine for preventing and / or treating depression. According to the invention, gammaCaMKII is enriched and expressed in hippocampal astrocytes, and the activity and the form of the astrocytes and the function of a glutamate transporter GLT1 are regulated, so that the hippocampal synaptic structure and the brain emotional function are further influenced. The expression deletion of gamma CaMKII in hippocampal astrocytes can cause depression-like behaviors of mice, and the regulation of a glucocorticoid signal channel can regulate the gamma CaMKII protein level in a targeted manner. In addition, the depression-like behavior of a chronic stress constraint model mouse can be obviously improved by overexpressing the gamma CaMKII in the hippocampal astrocyte. The invention provides a new insight for understanding a molecular mechanism of interaction of astrocytes and synapses, and provides a potential new target for discovery and screening of antidepressant drugs.